Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15336699 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL27821834 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL79422 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL14697303 | 0.75 | — | — | |
| SCHEMBL16849099 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL29259477 | 0.74 | — | — | |
| SCHEMBL28956000 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL519207 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL16211575 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL17510231 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382288-A1 | 8-AZA QUINAZOLINES AS BRAIN-PENETRANT SOS1-INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4658647-A1 | TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS | UCB Biopharma SRL (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250320228-A1 | PYRIDO[3,2-D]PYRIMIDINES AS HPK1 INHIBITORS | MERCK PATENT GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3126349-A1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-20160376237-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9303012-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160016951-A1 | NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016009076-A1 | NOVEL NAPHTHRYIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-01-21 | — | — | WO | disclosed |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928868-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| WO-2015150438-A1 | 5,6-DISUBSTITUTED PYRIDINE-2-CARBOXAMIDES AS CANNABINOID RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| CN-104854092-A | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE | 2015-08-19 | — | — | CN | disclosed |
| WO-2014086806-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |